Benitec Limited and China-based Biomics Biotechnologies Co. have signed a binding agreement to collaborate on an RNA interference treatment for chronic hepatitis B virus (HBV) infection. Benitec, an Australian biotechnology company, will contribute its proprietary DNA-directed RNAi (ddRNAi) technology. Biomics of Nantong has developed a full-sites siRNA library, drug target screening and identification, siRNA structure modification and drug delivery systems. More details...

Stock Symbol: (ASX: BLT)